《新股消息》據報寧波健世科技啟動預路演 籌3,000萬美元
外電引述消息人士指,中國醫療器械公司寧波健世科技已啟動預路演工作,就香港首次公開發售(IPO)評估投資者意向,預期將集資約3,000萬美元,由中金公司及花旗擔任聯席保薦人。
初步招股文件顯示,健世科技致力於開發用於治療結構性心臟病的介入產品,目前旗下瓣膜性心臟病及心力衰竭疾病在研產品合共達到10款,預期將於明年下半年至2025年進入商業化階段。
截至今年6月底止上半年,公司錄得約3,834.6萬元人民幣的其他收入及收益,期內淨虧損為7,285.3萬元人民幣,對比2021年同期的虧損3.68億元人民幣有所收窄。公司預期,由於現有核心項目將繼續產生大量研發開支,預期全年度仍將錄得虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.